Table of Contents Table of Contents
Previous Page  278 / 812 Next Page
Information
Show Menu
Previous Page 278 / 812 Next Page
Page Background

S274

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

Aims

To ensure that psychiatrists have sufficient knowledge

regarding rTMS. A good knowledge will most likely have a positive

impact on their attitude.

Methods

Cross-sectional study was conducted through an online

survey. The study population is all psychiatrists in Saudi Arabia. A

new valid and reliable questionnaire was developed.

Results

Sample of 96 psychiatrists enrolled in the study, 81%

were males. Participant’s mean age was 37 years. Half of partic-

ipants were consultants. The sample mainly consists of general

psychiatrists (65%). The study showed that 80% of psychiatrists

have an efficient knowledge about rTMS. Consultants have higher

knowledge than residents do. Abroad training has no association

with the level of knowledge or attitude. Seventy-nine percent of

psychiatrists have a positive attitude toward rTMS. Only 53% of psy-

chiatrists agreed to receive (rTMS) in case they were in a psychotic

depressive condition. Minority (7%) of psychiatrists would not refer

their patients for rTMS.

Conclusion

Most of psychiatrists have a good knowledge and a

positive attitude toward rTMS. Those who have high level of train-

ing and experience show higher level of knowledge. Articles are

found to be a better source for updating knowledge. Having an

rTMS treated person in the family or relatives will positively affect

the psychiatrist’s attitude.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.573

EW456

Changes in symptom severity and

biochemical markers of brain injury

in patients with treatment-resistant

schizophrenia

N. Petrova

1 ,

, M. Dorofeikova

1

, V. Dorofeykov

2

, M. Ivanov

3

,

D. Zubov

3

1

Saint Petersburg State university, medical faculty, Saint-Petersburg,

Russia

2

D.O. Ott research institute of obstetrics - gynecology and

reproductology, laboratory of biochemistry, Saint-Petersburg, Russia

3

Saint-Petersburg V.M. Bekhterev psychoneurological research

institute, department of biological therapy, Saint-Petersburg, Russia

Corresponding author.

One of the major problems of the methodology of translational

research is to find biomarkers that serve as indicators of treatment

response.

The aim was to study the dynamics of biochemical markers in the

process of combined antipsychotics and electroconvulsive therapy.

Material and methods

Present study was conducted in 34

patients with treatment-resistant schizophrenia (31.6

±

9.4 years

old) that underwent combined ECT (10 ECTs on average) and

pharmacological treatment. The assessment included PANSS and

determination of NSE and S100B protein concentrations using auto-

mated immunochemical analyzer “Elecsys 2010”. Blood samples

were obtained before the beginning of ECT, 24 hours after the third

and sixth ECTs.

Results

Average reduction of PANSS score was 29,1%, > 20% for

85% of patients. There were no significant differences in NSE and

S100B concentrations at different stages of treatment. This result

is consistent with data on the safety of ECT from the point of

view of the integrity of cells. There were found statistically sig-

nificant differences between S100B concentration in women and

men (60

±

18 and 43

±

23 ng/L, respectively,

P

= 0.029) and a trend

of increase in S100 levels with the increase of disease duration

(

r

= 0.372,

P

= 0.062). Serum S100B concentrations at baseline nega-

tively correlatedwith positive and negative symptoms severity and

with PANSS composite score. No correlation between treatment

efficiency and biochemical markers’ levels was found.

Conclusion

Combined antipsychotic and electroconvulsive ther-

apy was effective for treatment-resistant schizophrenic patients

and did not induce nerve cells damage. Initial symptom severity

was correlated with S100B levels.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.574

EW457

ECT-treatment in Western Norway;

first data from the Regional register of

neurostimulation treatment

U. Kessler

1 ,

, H. Schoeyen

2

1

Haukeland university hospital, clinic for psychosomatic medicine,

Bergen, Norway

2

Stavanger university hospital, department of psychiatry,

Stavangerno, Norway

Corresponding author.

Introduction

Electroconvulsive therapy (ECT) is one of the most

polarizing treatments inmedicine. Although the treatment effect is

well documented in clinical studies, there is a lack of data regarding

patients treated in an ordinary clinical setting. In 2013, we estab-

lished a regional register of neurostimulation treatment inWestern

Norway.

Objectives

To describe the use of ECT at the Haukeland university

hospital in Bergen.

Methods

Patients treated with ECT between June 2013 and June

2015 were included in the register.

Results

One hundred and forty-seven patients received ECT dur-

ing the 2 years period. The mean age was 58.4 years (22–91 years),

67% were female. Half of the patients (49.7%) had been treated

with ECT previously. Indication for treatment was depression in

137 patients (93.2%), of which 29 (19.7%) were moderately, and

69 patients (46.9%) severely depressed, and additional 37 patients

(25.2%) presented with severe depression with psychotic features.

All but two patients were treated with right unilateral electrode

placement, with a mean of 9.7 (3–22) treatments.

ThemeanMADRS before treatment was 34.2 (4–56) and after treat-

ment 11.9 (0–39). One hundred and ten patients (74.8%) responded

to treatment; of which 89 (60.5%) remitted (response defined as

a 50% or greater decrease from MADRS baseline score, remission

defined as MADRS

12). Twenty patients (13%) continued with

continuation or maintenance ECT after the index series.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.575

EW458

Repetitive transcranial magnetic

stimulation (rTMS) for the

management of treatment-resistant

depression in schizophrenia

S. Mosolov

, N. Maslenikov , E. Tsukarzi

Moscow research institute of psychiatry, therapy of mental disorders,

Moscow, Russia

Corresponding author.

Introduction

Depression is the most common co-occurring syn-

drome in schizophrenia, which affects up to 60% of patients.

Depression aggravates negative symptoms and cognitive deficit

and can deteriorate social functioning, quality of life and outcome

of the disease. Insufficient clinical response to adequate pharmaco-

therapy determines rising interest to brain stimulation techniques

such as rTMS.